AbbVie announced it has agreed to buy a drug-delivery device manufacturing facility in Tempe, Arizona, along with associated intellectual property, from West Pharmaceutical Services in a move designed to expand AbbVie’s capacity for producing devices used to administer its medicines.
Under the definitive agreement, AbbVie plans to invest more than $175 million to acquire the site, modernize it, and fully integrate it into the company’s global manufacturing network. AbbVie also expects to hire about 200 employees at the facility as it ramps up operations.
The acquisition is positioned as another step in AbbVie’s previously stated plan to invest more than $10 billion in U.S. capital spending over the next decade, with a focus on strengthening domestic manufacturing, supporting innovation, and expanding capacity for critical production needs.
AbbVie said the Tempe transaction includes the transfer of manufacturing facilities with multiple production lines, as well as 3.5 mL on-body injector technology. The company said the assets will support production for both current and next-generation medicines in its immunology and neuroscience franchises.
AbbVie noted it employs roughly 29,000 people across the U.S., including more than 6,000 workers at 11 domestic manufacturing sites, and said the Tempe expansion would increase its footprint and economic impact in Arizona. The deal is expected to close in mid-2026, subject to customary closing conditions.
KEY QUOTE:
“Over the next decade, AbbVie is investing more than $10 billion in capital to broadly support innovation and expand our manufacturing capabilities and capacity in the U.S. With this investment, AbbVie is strengthening our manufacturing capabilities, ensuring we are well-positioned to develop and deliver next-generation medicines that make a remarkable impact on patients’ lives.”
Robert A. Michael, Chairman and Chief Executive Officer, AbbVie
